GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
Consistent efficacy of GIOTRI® observed across real-world studies
Document ID: PC-MY-102822
03/02/2023
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-MY-102822
Production date: february 2023
Production date: february 2023